Nirsevimab (Beyfortus)
RSV Prevention in Infants
ApprovedCommercial
Key Facts
About GSK plc
GSK is a London-headquartered, publicly traded biopharma giant with a market cap of ~$109B, focused exclusively on pharmaceuticals and vaccines following the 2022 spin-off of its consumer health division. Its mission is to positively impact the health of 2.5 billion people by 2030 through disciplined R&D in four core therapeutic areas: Respiratory/Immunology, Oncology, HIV, and Infectious Diseases. The company leverages advanced genetic research, AI, and platform technologies to drive a pipeline of approximately 130 programs, aiming for sustained growth from both its established portfolio and novel pipeline assets.
View full company profileOther RSV Prevention in Infants Drugs
| Drug | Company | Phase |
|---|---|---|
| Beyfortus® (Nirsevimab) | Dr. Reddy's Laboratories | Launched |